**Question:** You started a patient on oral warfarin. Which of the following factors show the most rapid decline in the blood levels after the initiation of warfarin therapy?

A. Factor II (Prothrombin)
B. Factor VII
C. Factor X
D. Factor XII

**Core Concept:**
Warfarin is a vitamin K antagonist that inhibits the synthesis of clotting factors II, VII, IX, X, XII, and XIII in the liver. These factors are dependent on vitamin K for their synthesis. Vitamin K is an essential cofactor for the gamma-carboxylation of specific glutamic acid residues in these clotting factors, which is necessary for their activation.

**Why the Correct Answer is Right:**
The correct answer is D. Factor XII, also known as Haemophilus Facteur XII or Hageman factor, is the factor that shows the most rapid decline in blood levels after initiating warfarin therapy. Warfarin's action is primarily on vitamin K-dependent clotting factors, which include factors II, VII, IX, X, XII, and XIII.

Warfarin inhibits the synthesis of these factors by competitive inhibition of vitamin K reductase, the enzyme responsible for reducing vitamin K to its active form. As a result, vitamin K is not available to gamma-carboxylate the glutamic acid residues in these factors, leading to impaired activation of these clotting factors.

**Why Each Wrong Option is Incorrect:**
A. Factor II (Prothrombin): Factor II is not the most rapidly declining factor due to its long half-life.
B. Factor VII: Factor VII has a moderate half-life, but still not as rapid as Factor XII.
C. Factor X: Factor X has a moderate half-life, but still not as rapid as Factor XII.

**Clinical Pearl:**
The rapid decline of Factor XII levels indicates an effective inhibition of vitamin K synthesis by warfarin. Monitoring Factor XII levels can be useful in maintaining the therapeutic INR (International Normalized Ratio) in patients on warfarin therapy, as a higher INR indicates a more effective anticoagulation. Therefore, a decline in Factor XII levels can guide the dose adjustment of warfarin to achieve the desired therapeutic effect and minimize the risk of bleeding complications.